Conditions: Well-differentiated Pancreatic Neuroendocrine Tumor
Keywords: neuroendocrine tumors adenoma islet cells carcinoma islet cells pancreatic neoplasms angiogenesis inhibitors sunitinib neoplasms carcinoma adenoma
Enrollment: 106
Healthy volunteers: no

Brief summary:
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.

Detailed description:
This study is being conducted to meet regulatory post-marketing commitments.

Arms:
arm 1: None

Interventions: intervention 1: sunitinib
Intervention descriptions: intervention 1: Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.

Protocol document: